DA
ADPT icon

Duality Advisers’s Adaptive Biotechnologies ADPT Stock Holding History

Duality Advisers’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,684
Closed -$148K – 579
2022
Q1 		$148K Buy
+10,684
New +$168K 0.02% 606
2021
Q2 		– Sell
-58,064
Closed -$2.34M – 511
2021
Q1 		$2.34M Buy
+58,064
New +$3.14M 0.2% 178

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

Duality Advisers's ADPT Position: Q2 2022 in Review

Duality Advisers sold out of Adaptive Biotechnologies (ADPT) in Q2 2022, closing a stake of 10,684 shares — an estimated $148K sold.

Duality Advisers first reported a position in ADPT in Q1 2021 and held it in 2 quarters. The position peaked at $2.34M in Q1 2021. 209 funds tracked by Wall St. Rank hold ADPT as of Q2 2022.

  • Duality Advisers reported no remaining Adaptive Biotechnologies position as of Q2 2022 after selling out during the quarter.
  • Duality Advisers sold 10,684 Adaptive Biotechnologies shares in Q2 2022, an estimated $148K.
  • Duality Advisers first reported a position in Adaptive Biotechnologies in Q1 2021 and held it in 2 quarters.
  • Duality Advisers's Adaptive Biotechnologies position peaked at $2.34M in Q1 2021.
  • 209 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2022.

Based on Duality Advisers's 13F filing for Q2 2022, filed 8 Aug 2022.